The W. Garfield Weston Professor of Immunology,
Institut Weizmann. Weizmann Institute of Science, Department of Immunology (Rehovot, Israel).
Myasthenia Gravis, Multiple Sclerosis and Antibodies to ErbB Receptors
His research interests include peptide and protein chemistry and immunology, the molecular basis of antigenicity, genetic control of immune response, conformational changes in antigens and antibodies, the phenomenon of autoimmunity, synthetic vaccines against infectious and autoimmune diseases, multiple sclerosis, myasthenia gravis, graft-versus-host disease, catalytic antibodies, immunotargeting of anti-cancer drugs, and the ErbB family of receptor tyrosine kinases.
Immunomodulation of myasthenia gravis associated autoimmune responses by an altered peptide-ligand: mechanisms of action. M. Paas-Rozner, A. Faber-Elmann, M. Sela and E. Mozes, Satellite Meet. on Myasthenia Gravis, November 1998, Mysore, India, "MG Workshop Proceedings," P. Christadoss, ed., Narosa Publ. House, 2000, p. 182.
An altered peptide ligand inhibits the activities of matrix metalloproteinase-9 and phospholipase C, and inhibits T cell interactions with VCAM-1, induced in vivo by a myasthenogenic T cell epitope. A. Faber-Elmann, V. Grabovsky, M. Dayan, M. Sela, R. Alon and E. Mozes, FASEB J. 15, 187 (2001).
Inhibition of tumor growth by polyethylene glycol derivatives of anti-ErbB2 antibodies. E. Hurwitz, L.N. Klapper, M. Wilchek, Y. Yarden and M. Sela, Cancer Immunol. Immunotherapy 49, 226 (2000).
c-Cbl is a suppressor of the Neu oncogene. G. Levkowitz, S. Oved, L.N. Klapper, S. Lair, M. Sela and Y. Yarden, J. Biol. Chem. 275, 35532 (2000).
Cytokine profile and T cell adhesiveness to endothelial selections: In vivo induction by a myasthenogenic T cell epitope and immunomodulation by a dual altered peptide ligand. A. Faber-Elmann, V. Grabovsky, M. Dayan, M. Sela, R. Alon and E. Mozes, Intl. Immunol.
Oral administration of a dual analog of two myasthenogenic T cell epitopes down regulates experimental autoimmune myasthenia gravis in mice. M. Paas-Rozner, M. Dayan, Y. Paas, J.-P. Changeux, I. Wirguin, M. Sela and E. Mozes. Proc. Natl. Acad. Sci. U.S. 97, 2168 (2000).
Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone. T. Brenner, R. Arnon, M. Sela, O . Abramsky, Z. Meiner, R. Riven-Kreitman, N. Tarcik and D. Teitelbaum. J. Neuroimmunology 115, 152 (2001).
T-Cell immunity to Copolymer-1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. J. Kipnis, E. Yoles, Z. Porat, F. Mor, M. Sela, I.R. Cohen and M. Schwartz, Proc. Natl. Acad. Sci. U.S. 97, 7446 (2000).
Tumor-inhibitory antibodies to HER2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER2. L.N. Klapper, H. Waterman, M. Sela and Y. Yarden, Cancer Research 60, 3384 (2000).
An altered peptide ligand immunomodulates specific myasthenogenic T cell responses via immunosuppressive cytokines. M. Paas-Rozner, M. Sela and . Mozes, J. Neuroimmunology.
Specific Th2 cells accumulate in the central nervous system of mice protected against EAE by copolymer 1. R. Aharoni, D. Teitelbaum, O. Leitner, A. Meshorer, M. Sela and R. Arnon, Proc. Natl. Acad. Sci. U.S. 97, 11472 (2000).
Specific inhibition of the reaction between a tumor-inhibitory antibody and the ErbB-2 receptor by a mimotope derived from a phage display library. N. Vaisman, A. Nissim, L.N. Klapper, B. Tirosh, Y. Yarden and M. Sela, Immunology Letters 75, 61 (2000).
Copolymer 1 inhibits manifestations of graft rejection. R. Aharoni, D. Teitelbaum, R. Arnon and M. Sela, Transplantation.
Review Articles, Books, Lectures, Chapters
The concept of specific immune treatment against autoimmune diseases. M. Sela, Intern. Rev. Immunol. 18, 201 (1999).
Development of copolymer 1 (Copaxone) as a specific drug against multiple sclerosis. D. Teitelbaum, R. Aharoni, M. Fridkis-Hareli, R. Arnon and M. Sela, in "The Decade of Autoimmunity," Y. Shoenfeld, ed. p. 191 (1999), Elsevier Science, publ.
The involvement of myasthenogenic T cell epitopes and their analogs in the clinical manifestations and treatment of myasthenia gravis. E. Mozes and M. Sela, in "The Decade of Autoimmunity," Y. Shoenfeld, ed., p. 245 (1999), Elsevier Science, publ.
Poly-a-amino acids - from a better understanding of immune phenomena to a drug a against multiple sclerosis. M. Sela, Acta Polymerica 49, 523 (1998).
AFIRST, 14 ans de cooperation. M. Sela, Daguesh No. 33, p. 1 (1998).
In praise of Irun Cohen. M. Sela
AFIRST, quatorze ans de cooperation. M. Sela, La Jaune et la Rouge, No. 537, p. 49, 1998.
Structural components responsible for peptide antigenicity. M. Sela, Applied Biochemistry and Biotechnology, 83, 63 (2000).
Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. L.N. Klapper, M.H. Kirschbaum, M. Sela and Y. Yarden, Adv. Cancer Research (Eds. G.F. Van de Wonde and G. Klein) 77, 25 (2000).
The concept of specificity in peptide vaccines for infectious, autoimmune and neoplastic diseases. M. Sela and R. Arnon, in "Science at the Turn of the Millenium," ed. E. Keinan,
Specific vaccines against autoimmune diseases. M. Sela, Compt. rend. Acad. Sci., Serie III, 322, 933 (1999).
Help for the aged and the disabled- the case of multiple sclerosis. The Carta of Human Duties M. Sela, Proc. Intl. Forum, June 20, 1998, San Vito al Tagliamento, Italy, p. 143 (1999).
Assistenza per gli anziani e i disabili - il caso della sclerosi multiple. M. Sela, La Carta dei Doveri Umani, Proc. Intl. Forum, June 20, 1998. San Vito al Tagliamento, Italia, p. 33 (1999).
The chemistry of the Copaxone Drug. R. Arnon and M. Sela, Chemicals in Israel, I, 16 (1999).
The concept of specificity in treating autoimmune diseases. M. Sela, Intl. J. Immunorehabilitation, 2, 12 (2000).
Cancer immunotherapy directed at growth factor receptors: the ErbB/HER network as a prototype. M. Sela, B. Schechter and Y. Yarden, in "Targeted therapy for cancer", K.N. Syrigos and K.J. Harrington, eds.
Glatiramer acetate (copolymer 1) in the treatment of multiple sclerosis. M. Sela and D. Teitelbaum, Expert Opinion on Pharmacotherapy.